HC Wainwright Forecasts Strong Price Appreciation for Karyopharm Therapeutics (NASDAQ:KPTI) Stock

Karyopharm Therapeutics (NASDAQ:KPTI) had its target price boosted by analysts at HC Wainwright from $7.00 to $56.00 in a report released on Wednesday,Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright also issued estimates for Karyopharm Therapeutics’ Q1 2025 earnings at ($0.29) EPS, Q3 2025 earnings at ($0.25) EPS, Q4 2025 earnings at ($0.28) EPS, FY2025 earnings at ($1.10) EPS, FY2026 earnings at ($0.87) EPS and FY2027 earnings at ($0.46) EPS.

Several other brokerages also recently issued reports on KPTI. StockNews.com downgraded shares of Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, November 22nd. Royal Bank of Canada reaffirmed an “outperform” rating and set a $3.00 price target on shares of Karyopharm Therapeutics in a report on Thursday, February 20th. Finally, Piper Sandler lifted their price target on shares of Karyopharm Therapeutics from $4.00 to $5.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 6th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, Karyopharm Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $17.25.

Karyopharm Therapeutics Stock Performance

NASDAQ KPTI opened at $0.57 on Wednesday. The firm has a market capitalization of $72.07 million, a price-to-earnings ratio of -0.56 and a beta of 0.06. Karyopharm Therapeutics has a one year low of $0.51 and a one year high of $1.70. The company’s 50 day moving average price is $0.66 and its 200 day moving average price is $0.75.

Karyopharm Therapeutics (NASDAQ:KPTI) last released its quarterly earnings data on Wednesday, February 19th. The company reported ($0.24) EPS for the quarter, beating the consensus estimate of ($0.26) by $0.02. The company had revenue of $30.54 million during the quarter, compared to analysts’ expectations of $30.29 million. Sell-side analysts forecast that Karyopharm Therapeutics will post -0.71 EPS for the current fiscal year.

Hedge Funds Weigh In On Karyopharm Therapeutics

Several large investors have recently modified their holdings of KPTI. Geode Capital Management LLC increased its holdings in Karyopharm Therapeutics by 2.7% in the fourth quarter. Geode Capital Management LLC now owns 1,392,314 shares of the company’s stock valued at $942,000 after buying an additional 36,922 shares during the last quarter. Silverarc Capital Management LLC grew its position in shares of Karyopharm Therapeutics by 6.7% in the 4th quarter. Silverarc Capital Management LLC now owns 595,990 shares of the company’s stock worth $403,000 after acquiring an additional 37,524 shares in the last quarter. Velan Capital Investment Management LP bought a new stake in shares of Karyopharm Therapeutics in the 4th quarter valued at approximately $27,000. Two Sigma Advisers LP raised its position in shares of Karyopharm Therapeutics by 145.5% during the 4th quarter. Two Sigma Advisers LP now owns 76,600 shares of the company’s stock valued at $52,000 after acquiring an additional 45,400 shares in the last quarter. Finally, Focus Partners Wealth acquired a new stake in shares of Karyopharm Therapeutics during the 4th quarter valued at approximately $31,000. Institutional investors own 66.44% of the company’s stock.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).